

1-1-1990

## Where all the glucose doesn't go in non-insulin-dependent diabetes mellitus

C Bogardus

Stephen Lillioja

*University of Wollongong*, [lillioja@uow.edu.au](mailto:lillioja@uow.edu.au)

Follow this and additional works at: <https://ro.uow.edu.au/medpapers>



Part of the [Medicine and Health Sciences Commons](#)

---

### Citation

Bogardus, C and Lillioja, Stephen, 1990, Where all the glucose doesn't go in non-insulin-dependent diabetes mellitus, 262-263.

<https://ro.uow.edu.au/medpapers/166>

---

## Where all the glucose doesn't go in non-insulin-dependent diabetes mellitus

### Abstract

REDUCED insulin-mediated glucose uptake, or insulin resistance, is a metabolic defect characteristic of virtually all patients with non-insulin-dependent diabetes mellitus (NIDDM). The cause of insulin resistance remains unknown, but in the past decade, since the development of the hyperinsulinemic-glucoseclamp technique, considerable progress has been made in identifying the insulin-resistant tissues and metabolic pathways responsible for decreased insulin action. DeFronzo et al. 1,2 and subsequently others demonstrated that most of the glucose that leaves the plasma during hyperinsulinemia enters peripheral tissues rather than the gut or liver, and that insulin resistance in patients with NIDDM is largely a result of decreased glucose uptake by these peripheral tissues. Since little of the glucose taken up by peripheral tissues under the mediation of insulin could be recovered from adipose tissue, investigators concluded that most of the glucose was taken up by skeletal muscle.

### Disciplines

Medicine and Health Sciences

### Publication Details

Bogardus, C. & Lillioja, S. (1990). Where all the glucose doesn't go in non-insulin-dependent diabetes mellitus. *New England Journal of Medicine*, 322 (4), 262-263.

# The New England Journal of Medicine

Owned and Published by the  
Massachusetts Medical Society

William G. Lavelle, M.D.  
*President*

William M. McDermott, Jr., M.D.  
*Executive Vice President*

Charles S. Amoroso, Jr.  
*Executive Secretary*

## THE COMMITTEE ON PUBLICATIONS OF THE MASSACHUSETTS MEDICAL SOCIETY

James F. McDonough, M.D., *Chairman*

Henry H. Banks, M.D.

Edward E. Jacobs, Jr., M.D.

Frank E. Bixby, Jr., M.D.

Brian J. McKinnon

Howard M. Ecker, M.D.

Daniel Miller, M.D.

Howard Epstein, M.D.

Percy W. Wadman, M.D.

Arnold S. Relman, M.D., *EDITOR-IN-CHIEF*  
Marcia Angell, M.D., *EXECUTIVE EDITOR*  
Edwin W. Salzman, M.D., *DEPUTY EDITOR*  
Gregory D. Curfman, M.D., *DEPUTY EDITOR*  
Edward W. Campion, M.D., *DEPUTY EDITOR*  
Robert D. Utiger, M.D., *DEPUTY EDITOR*

### ASSOCIATE EDITORS

Jane F. Desforges, M.D.

Morton N. Swartz, M.D.

Ronald A. Malt, M.D.

Franklin H. Epstein, M.D.

Lee Goldman, M.D.

Francis D. Moore, M.D., *BOOK REVIEW EDITOR*

John C. Bailar, III, M.D., Walter Willett, M.D.,  
*STATISTICAL CONSULTANTS*

John K. Iglehart, *NATIONAL CORRESPONDENT*

Marlene A. Thayer, *EDITORIAL OFFICE MANAGER*

Stephen E. Cinto, *MANAGER OF EDITORIAL PRODUCTION*

Lorraine W. Loviglio, *MANAGER OF MANUSCRIPT EDITING*

### EDITORIAL BOARD

Mary Ellen Avery, M.D.

Peter T. Macklem, M.D.

David Baltimore, Ph.D.

Robert J. Mayer, M.D.

John G. Bartlett, M.D.

Kenneth McIntosh, M.D.

Eugene Braunwald, M.D.

Stuart H. Orkin, M.D.

Harvey R. Colten, M.D.

Peter Reich, M.D.

Robert M. Donaldson, Jr., M.D.

Uwe E. Reinhardt, Ph.D.

Richard H. Egdahl, M.D.

B. Lawrence Riggs, M.D.

Bernard G. Forget, M.D.

Lewis P. Rowland, M.D.

Antonio M. Gotto, Jr., M.D., D.Phil.

Kenneth J. Ryan, M.D.

Thomas B. Graboys, M.D.

Harold C. Sox, M.D.

Martin S. Hirsch, M.D.

Paul D. Stolley, M.D.

Norman K. Hollenberg, M.D., Ph.D.

Jean D. Wilson, M.D.

### EDITORIAL OFFICES

Helen Connors, Research Assistant; Karen M. Daly, Editorial Assistant; Briana Doherty, Editorial Assistant; Kathleen Eagan, Manuscript Assistant; Dale R. Golden, Editorial Assistant; Kate L. Haas, Editorial Production Assistant; Christie L. Hager, Editorial Assistant; Rebecca H. Hale, Editorial Assistant; Susan L. Kaplan, Editorial Production Layout Artist; David F. March, Manuscript Editor; Sandra S. McLean, Manuscript Editor; Brian Middleton, Editorial Assistant; Henry S. Miller, Jr., Manuscript Editor; Stephen Morrissey, Manuscript Editor; Sylvia L. Parsons, Editorial Assistant; Marilyn Seaquist, Receptionist; Deborah A. Stone, Senior Editorial Production Coordinator; Pamela S. Stryjewski, Editorial Production Proofreader; Marc E. Tissenbaum, Editorial Production Assistant; Nancy B. Watkins, Editorial Production Assistant.

Frederick Bowes, III, *DIRECTOR OF PUBLISHING OPERATIONS*  
Ann Reinke Strong, *DEPUTY DIRECTOR*

## WHERE ALL THE GLUCOSE DOESN'T GO IN NON-INSULIN-DEPENDENT DIABETES MELLITUS

REDUCED insulin-mediated glucose uptake, or insulin resistance, is a metabolic defect characteristic of virtually all patients with non-insulin-dependent diabetes mellitus (NIDDM). The cause of insulin resistance remains unknown, but in the past decade, since the development of the hyperinsulinemic-glucose-clamp technique, considerable progress has been made in identifying the insulin-resistant tissues and metabolic pathways responsible for decreased insulin action. DeFronzo et al.<sup>1,2</sup> and subsequently others demonstrated that most of the glucose that leaves the plasma during hyperinsulinemia enters peripheral tissues rather than the gut or liver, and that insulin resistance in patients with NIDDM is largely a result of decreased glucose uptake by these peripheral tissues. Since little of the glucose taken up by peripheral tissues under the mediation of insulin could be recovered from adipose tissue, investigators concluded that most of the glucose was taken up by skeletal muscle.

Skeletal muscle oxidizes glucose to carbon dioxide and water or converts glucose to lactate or glycogen (or both) by so-called "nonoxidative" pathways. The production of carbon dioxide, and thereby the oxidation of glucose, can be measured according to the classic method of indirect calorimetry. Studies in which this technique was combined with the hyperinsulinemic-glucose-clamp procedure revealed that most of the glucose taken up by skeletal muscle was metabolized by the nonoxidative pathway and that decreased metabolism by this pathway was largely responsible for decreased glucose uptake in patients with insulin resistance, whether or not they had NIDDM.<sup>1,3</sup> Since little of the glucose taken up appeared as lactate, the working hypothesis was that insulin resistance in patients with NIDDM was mainly the result of decreased insulin-mediated glycogen synthesis by skeletal muscle.

Direct proof of this hypothesis was difficult. When insulin and glucose were infused, direct assay of sam-

PROSPECTIVE authors should consult "Information for Authors," which appears in the first issue of each month and may be obtained from the *Journal* Editorial Office (address below).

ARTICLES with original material are accepted for consideration with the understanding that, except for abstracts, no part of the data has been published, or will be submitted for publication elsewhere, before appearing here.

NOTICES should be sent at least 30 days before publication date.

THE *Journal* does not hold itself responsible for statements made by any contributor. Statements or opinions expressed in the *Journal* reflect the views of the author(s) and not the official policy of the Massachusetts Medical Society unless so stated.

ALTHOUGH all advertising material is expected to conform to ethical standards, acceptance does not imply endorsement by the *Journal*.

MATERIAL printed in the *Journal* is covered by copyright. No part of this publication may be reproduced or transmitted in any form without written permission.

FOR information on subscriptions, permissions, reprints, and other services see the "Business Information for Readers" page preceding the Classified Advertising section.

EDITORIAL OFFICES: 10 Shattuck St., Boston, MA 02115-6094.

Telephone: (617) 734-9800. FAX: (617) 734-4457.

BUSINESS, SUBSCRIPTION OFFICES: 1440 Main St., Waltham, MA 02154-1649.

ples of skeletal-muscle tissue obtained by percutaneous biopsy most often showed little or no change in glycogen content. This was not surprising, however, because of the small increases in glycogen content expected in view of the large mass of skeletal muscle and the relatively low sensitivity of the methods used. Some improvement in sensitivity was obtained when radiolabeled glucose was used, and Young et al.<sup>4</sup> found that glycogen accumulation was decreased in the muscle of nondiabetic subjects with insulin resistance, as compared with normal subjects. Since the rate-limiting enzyme in the conversion of glucose to glycogen is glycogen synthase, the most convincing evidence, albeit indirect, that insulin-mediated, nonoxidative glucose metabolism was actually due to glycogen synthesis in skeletal muscle was the positive correlation found between the insulin-mediated, nonoxidative metabolism of glucose and the activation of skeletal-muscle glycogen synthase.<sup>5,6</sup> Nonetheless, without direct evidence of glycogen accumulation in skeletal muscle after insulin and glucose infusions, there was no final proof of where all the glucose was going or, more important for the diabetic patient with insulin resistance, where the glucose was not going.

In this issue of the *Journal*, Shulman et al.<sup>7</sup> have convincingly answered these questions, using a novel application of nuclear magnetic resonance spectroscopy. They found that the insulin-mediated, nonoxidative metabolism of glucose is due largely to glycogen synthesis by skeletal muscle. They also demonstrated the important fact that insulin resistance in patients with NIDDM is mostly a result of a defect in this metabolic pathway. Thus, we now have a clearly defined metabolic pathway that has been proved to be disturbed in NIDDM.

There are many potential sites for a defect leading to abnormalities of insulin-mediated glycogen synthesis by muscle. For insulin to act, it must first traverse the unfenestrated capillary endothelium before it is bound to its specific receptor in the muscle membrane. This binding leads to a wide range of effects, including activation of the receptor tyrosine kinase, initiation of a series of phosphorylation-dephosphorylation reactions, and stimulation of glucose transport. Already, abnormalities of insulin regulation of skeletal-muscle-receptor tyrosine kinase activity and glycogen synthase activity have been described in patients with NIDDM.<sup>5,6,8</sup> In addition, our colleagues have recently found that insulin activation of glycogen synthase phosphatase, an enzyme that dephosphorylates and activates glycogen synthase, is reduced in subjects with insulin resistance (unpublished data). Glucose transport in skeletal muscle has been difficult to study in humans, and few data are available on patients with diabetes. Further studies of the insulin-regulated proteins involved in glycogen synthesis by muscle should lead to the delineation of the mechanism or mechanisms of insulin resistance in NIDDM.

However, studies of patients alone will not resolve

whether any observed defects precede the onset of the disease and are in some way causative, or whether these defects are secondary to the disease itself. Recent family and population studies suggest that insulin resistance is present in nondiabetic persons in whom NIDDM later develops.<sup>9</sup> Interestingly, Eriksson et al., in a recent article in the *Journal*,<sup>10</sup> found that rates of insulin-mediated, nonoxidative glucose metabolism were decreased in the first-degree relatives of patients with NIDDM. On the basis of these studies and the work of Shulman et al.,<sup>7</sup> the hypothesis naturally arises that a defect in insulin-mediated glycogen synthesis by skeletal muscle may underlie and contribute to the development of NIDDM.

National Institute of  
Diabetes and Digestive  
and Kidney Diseases  
Phoenix, AZ 85016

CLIFTON BOGARDUS, M.D.  
STEPHEN LILLIOJA, M.B., CH.B.,  
F.R.A.C.P.

#### REFERENCES

- DeFronzo RA, Jacot E, Jéquier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry and hepatic and femoral venous catheterization. *Diabetes* 1981; 30:1000-7.
- DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. *J Clin Invest* 1985; 76:149-55.
- Lillioja S, Mott DM, Zawadzki JK, Young AA, Abbott WG, Bogardus C. Glucose storage is a major determinant of in vivo "insulin resistance" in subjects with normal glucose tolerance. *J Clin Endocrinol Metab* 1986; 62:922-7.
- Young AA, Bogardus C, Wolfe-Lopez D, Mott DM. Muscle glycogen synthesis and disposition of infused glucose in humans with reduced rates of insulin-mediated carbohydrate storage. *Diabetes* 1988; 37:303-8.
- Bogardus C, Lillioja S, Stone K, Mott D. Correlation between muscle glycogen synthase activity and in vivo insulin action in man. *J Clin Invest* 1984; 73:1185-90.
- Mandarino LJ, Wright KS, Verity LS, et al. Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase: evidence for their role in oxidative and nonoxidative glucose metabolism. *J Clin Invest* 1987; 80:655-63.
- Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by <sup>13</sup>C nuclear magnetic resonance spectroscopy. *N Engl J Med* 1989; 322:223-8.
- Caro JF, Sinha MK, Raju SM, et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin-dependent diabetes. *J Clin Invest* 1987; 79:1330-7.
- Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. *Lancet* 1989; 1:1356-9.
- Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. *N Engl J Med* 1989; 321:337-43.

---

## SOUNDING BOARD

### U.S. MEDICAL PRACTICE BEFORE MEDICARE AND NOW — DIFFERENCES AND CONSEQUENCES

THE 1965 law establishing Medicare was a catalyst for change in the conditions of medical practice in the United States. This article reviews the law's effects, other changes occurring in the same period, and their consequences. It suggests why the morale of today's doctors is low, why they are more open to change than